News

New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Deliver 30% Savings, Halve Timelines and Cut Risk for Biotechs

4 June 2024

New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Deliver 30% Savings, Halve Timelines and Cut Risk for Biotechs

Avance Clinical is sharing new data at BIO 2024 from Frost & Sullivan research showing biotechs save more than 30% in costs and halve start-up times with CROs that have in-house scientific and regulatory affairs.

  • Reset
Avance Clinical Announces at BIO 2022: Expansion Across Australia and New Zealand – New Offices and Double Growth

9 June 2022

Avance Clinical Announces at BIO 2022: Expansion Across Australia and New Zealand – New Offices and Double Growth

Avance Clinical, the largest premium Australian Contract Research Organization (CRO) for international biotechs, has opened new offices in Sydney and Melbourne, with further expansions planned, and increased clinical staff numbers across the region to support double growth figures.

Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 – Best Contract Research Organization in APAC

19 April 2022

Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 – Best Contract Research Organization in APAC

Avance Clinical, the largest premium Australian Contract Research Organization (CRO) for international biotechs, has been selected as a finalist for the Best Contract Research Organization in APAC by Informa Pharma Intelligence.

Avance Clinical Announces New Office Opening in Melbourne

31 March 2022

Avance Clinical Announces New Office Opening in Melbourne

Avance Clinical, the Australian CRO for biotechs, has expanded into North America with the acquisition of CRO partner company C3 Research Associates to enable biotech clients a seamless journey from early phase to later phase studies. Avance Clinical has backing from private equity group Riverside Company for their global expansion program.

Avance Clinical Announces Appointment of Liahna Toy as Head of Business Development

3 March 2022

Avance Clinical Announces Appointment of Liahna Toy as Head of Business Development

Avance Clinical, the largest full-service Australian Contract Research Organization (CRO) for international biotechs, announced today the appointment of Liahna Toy to the new senior executive role, Head of Business Development.

Brett Favre Talks Concussion

2 March 2022

Brett Favre Talks Concussion

Listen to football legend Brett Favre on 5AA ‘Rowey’s Sports Show’ talk about concussion in sport and the therapy that leading biotech firm Odyssey Health as in clinical trials with Australia’s CRO Avance Clinical.

Avance Clinical Announces New Office Opening in Sydney

14 February 2022

Avance Clinical Announces New Office Opening in Sydney

Avance Clinical, the largest premium Australian Contract Research Organization (CRO) for international biotechs, has opened new offices in Sydney to support its growing clinical team in the greater Sydney region.

Avance Clinical Featured in Endpoints News on Cell & Gene Therapy Capabilities

25 November 2021

Avance Clinical Featured in Endpoints News on Cell & Gene Therapy Capabilities

The cell and gene therapies (CGT) sector offers unprecedented opportunities for patient disease management across virtually all therapeutic areas.

Avance Clinical Featured in Fierce Biotech on Intranasal Expertise

23 October 2021

Avance Clinical Featured in Fierce Biotech on Intranasal Expertise

With the global intranasal drug delivery market estimated to reach up to $71 billion over the next five years, Avance Clinical is seeing an increase in biotech clinical trials targeting this growing market demand.

XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain

18 October 2021

XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain

Avance Clinical's client XWPharma Ltd. has announced dosing of subjects in its first-in-human study evaluating XW10508, the Company’s novel, patented, glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy for the treatment of treatment-resistant depression and chronic pain.

Avance Clinical Awarded Frost & Sullivan 2021 Asia-Pacific CRO Best Practices Award for Customer Value Leadership

10 August 2021

Avance Clinical Awarded Frost & Sullivan 2021 Asia-Pacific CRO Best Practices Award for Customer Value Leadership

Avance Clinical has been awarded the prestigious Frost & Sullivan 2021 Asia-Pacific CRO Customer Value Leadership Award, the second consecutive Asia-Pacific (APAC) CRO Best Practices Award for the company from Frost & Sullivan.

XWPharma Announces Positive Results from Phase 1 Clinical Trials of XW10172, in Development as Once-Nightly Therapy for Sleep Disorders in Patients with Neurodegenerative Diseases

9 July 2021

XWPharma Announces Positive Results from Phase 1 Clinical Trials of XW10172, in Development as Once-Nightly Therapy for Sleep Disorders in Patients with Neurodegenerative Diseases

The leading Australian CRO for international biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical today congratulated client XWPharma on receiving positive results from its Phase 1 clinical trial of XW10172.

Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia

9 July 2021

Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia

The largest Australian full-service CRO for international biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical today congratulated client Tetherex Pharmaceuticals on first patient dosing for its Phase 1 vaccine clinical trial.

Proven industry
experience & expertise

500+

Studies in the past 5 years

330+

Experienced team members

18k+

Participants past 5 years

30

Years of CRO experience